Morris Hosseini
Morris Hosseini is a Senior Partner in our Pharma & Healthcare team in Berlin. He advises global clients on commercial strategies, including go-to-market models, medical affairs and market access topics. His consulting practice also focuses on digital transformation, including multi-channel approaches, and performance topics such as operational excellence, research and development and organizational effectiveness, including change management. Prior to joining Roland Berger, Morris Hosseini worked as a researcher in regenerative medicine and co-founded a biotech company on stem cell applications in Canada. He holds a Ph.D. in Biomedical Engineering from the University of Toronto in Canada.
Medicine is increasingly becoming predictive, preventive, personalized and participatory. This will create challenges and opportunities to leverage novel therapeutic strategies.
Global MedTech: Balancing innovation and operational efficiency
STUDY, February 20, 2025
Future of health 6 - The AI (r)evolution in health
Study, November 20, 2024
Global Pharma Study 2024 – a new age of performance programs
Study, October 22, 2024
The era of free drug-pricing in the US has come to an end
Article, September 17, 2024
Unlocking value in the CDMOs market
Article, July 3, 2024
US pharmaceutical pricing at a crossroads
Article, February 5, 2024
Cell and gene therapies: Strategies for commercial success
Article, November 14, 2023
Future of health 5 - A long and healthy life
Study, November 8, 2023
Cutting the cost of gene therapy manufacturing
Article, July 6, 2023
Beyond the numbers: Key characteristics of successful pharma companies
Study, May 24, 2023
Location matters
Article, April 20, 2023
Will environmental sustainability hold sway over the pharmaceuticals industry?
Article, November 29, 2022
M&A opportunities in biotechnology
Article, November 7, 2022
Future of health 4 – The patients of tomorrow
Focus, September 28, 2022
Mastering supply chain crises in the pharmaceutical industry
Article, July 11, 2022
The future of primary care in the Kingdom of Saudi Arabia
Study, June 27, 2022
Gaining competitiveness with Next Generation Manufacturing
Study, March 24, 2022
MedTech@Hospital 2021
Flyer, November 29, 2021
Future of health 3 - How the phygital model is going to transform healthcare
Study, September 24, 2021
Cell and gene therapies: Pharma's next big wave
Study, May 5, 2021
Growth ahead: German hospitals need MedTech companies more than ever
Study, November 20, 2020
Future of health 2 – The rise of healthcare platforms
Study, September 30, 2020
Supply bottlenecks for antibiotics due to corona pandemic: crisis with announcement
Article, March 25, 2020
Performance Improvement: How pharma businesses can safeguard viable margins
White paper, January 29, 2020
The Future of Medical Affairs: Creating value as never before
White paper, December 11, 2019
Future of health - Digitalization in the healthcare sector
Study, October 22, 2019
Regenerative medicine
Study, October 2, 2017
Reliability of antibiotics supply in Germany
Study, August 4, 2017
Digital and disrupted: All change for healthcare
Think:Act, September 28, 2016
Wearable tech: The next big thing in healthcare?
Point of view, May 21, 2016
Digital transformation in the healthcare space
Study, April 20, 2015
Saudi Arabian pharmaceuticals
Study, October 12, 2014